@article{cf3053862bc0441dbab5f44c6a154a21,
title = "Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain",
abstract = "A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.",
author = "Huang, {Ping Han} and Tsai, {Hsiao Han} and Liao, {Bo Hung} and Lin, {Yi Ling} and Jan, {Jia Tsrong} and Tao, {Mi Hua} and Chou, {Yu Chi} and Hu, {Che Ming Jack} and Chen, {Hui Wen}",
note = "Funding Information: This study was supported by the Ministry of Science and Technology (MOST-109-3114-Y-001-001 and MOST-109-2327-B-002-009), National Taiwan University and Academia Sinica, Taiwan. We thank Dr. Alex Ma in Genomics Research Center, Academia Sinica for providing the cDNA. Publisher Copyright: {\textcopyright} 2020 Taylor & Francis Group, LLC.",
year = "2021",
doi = "10.1080/21645515.2020.1814098",
language = "English",
volume = "17",
pages = "654--655",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "3",
}